BA
Bafna Pharmaceuticals Ltd (BAFNAPH)
₹469.95
Mkt cap
₹1,111 Cr
P/E ratio
96.40
P/B
10.78
Div yield
0.00%
ROE
12.30%
ROCE
11.90%
EPS (TTM)
₹4.88
Book value
₹44
52W range
95–502
Sector
Healthcare
Price history
Previous close
Incorporated in 1981, Bafna Pharmaceuticals Ltd manufactures finished pharmaceutical formulations [1]
NSE BAFNAPHBSE 532989
Health check
Cautious
ValuationExpensive
ProfitabilityAverage
GrowthLow
TechnicalsBullish
52-week range
−6.32% from high₹470
₹95+395.88% from low₹502
Current
₹469.95
Prev close
₹479.50
Day
−1.99%
Price performance
1D
−1.99%
1W
−2.51%
1M
+3.98%
3M
+97.71%
6M
+245.96%
1Y
+159.40%
YTD
+210.92%
Financials
Revenue, profit & margin
P/E ratio
96.4×
BAFNAPH is 197% above the sector median of 32.5×
BAFNAPH96.4×
Sector median32.5×
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 40.68 | 28.44 | 41.40 | 33.29 | 40.32 | 33.19 | 39.06 | 34.62 | 35.47 | 38.29 | 42.24 | 26.58 | 47.67 | |
| YoY Sales growth | +85.25% | -16.89% | -1.99% | -20.64% | -0.88% | +16.70% | -5.65% | +4.00% | -12.03% | +15.37% | +8.14% | -23.22% | +34.40% | |
| Expenses | 36.67 | 30.51 | 38.51 | 32.08 | 36.53 | 30.13 | 35.95 | 29.55 | 31.19 | 35.24 | 38.69 | 25.69 | 39.06 | |
| Operating Profit | 4.01 | -2.07 | 2.89 | 1.21 | 3.79 | 3.06 | 3.11 | 5.07 | 4.28 | 3.05 | 3.55 | 0.89 | 8.61 | |
| OPM % | 9.86% | -7.28% | 6.98% | 3.63% | 9.40% | 9.22% | 7.96% | 14.64% | 12.07% | 7.97% | 8.40% | 3.35% | 18.06% | |
| Other Income | 0.16 | 0.98 | 0.52 | 0.16 | 1.02 | 0.18 | -0.76 | 0.60 | 1.18 | 1.22 | 1.76 | 1.91 | 1.13 | |
| Interest | 0.44 | 0.58 | 0.68 | 0.65 | 0.62 | 0.64 | 0.82 | 0.91 | 0.86 | 0.86 | 1.03 | 0.94 | 1.02 | |
| Depreciation | 1.24 | 1.27 | 1.27 | 1.44 | 1.58 | 1.66 | 0.22 | 1.37 | 1.47 | 1.57 | 1.66 | 1.78 | 1.87 | |
| Profit before tax | 2.49 | -2.94 | 1.46 | -0.72 | 2.61 | 0.94 | 1.31 | 3.39 | 3.13 | 1.84 | 2.62 | 0.08 | 6.85 | |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -4.96% | 0.00% | 0.00% | |
| Net Profit | 2.48 | -2.94 | 1.46 | -0.72 | 2.62 | 0.95 | 1.31 | 3.39 | 3.12 | 1.84 | 2.75 | 0.08 | 6.85 | |
| EPS in Rs | 1.05 | -1.24 | 0.62 | -0.30 | 1.11 | 0.40 | 0.55 | 1.43 | 1.32 | 0.78 | 1.16 | 0.03 | 2.90 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Sep 202675.00%Promoter
Promoters75.00%
FIIs9.34%
Public15.66%
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,884.90 | 36.70 | 4,51,538 | 0.85% | 1,995 | −10.53% | 16,199 | +11.88% | 20.53% |
| Divi's Lab. | ₹11,180.50 | 86.86 | 2,96,807 | 0.27% | 1,127 | +63.57% | 3,676 | +35.40% | 21.97% |
| Torrent Pharma. | ₹4,689.50 | 82.07 | 1,78,180 | 0.81% | 534 | −10.03% | 4,979 | +50.79% | 15.19% |
| Laurus Labs | ₹2,294.60 | 92.69 | 1,24,195 | 0.09% | 436 | +126.43% | 2,206 | +33.44% | 17.76% |
| Zydus Lifesci. | ₹1,200.00 | 26.48 | 1,19,990 | 0.08% | 928 | −27.96% | 7,910 | +29.17% | 21.14% |
| Dr Reddy's Labs | ₹1,390.20 | 41.56 | 1,16,360 | 0.58% | 913 | −31.35% | 8,698 | −1.48% | 13.04% |
| Cipla | ₹1,415.00 | 36.88 | 1,14,518 | 0.92% | 852 | −35.05% | 7,404 | −2.44% | 15.49% |
| Bafna Pharma. | ₹469.95 | 96.44 | 1,111 | 0.00% | 7 | +119.55% | 48 | +34.40% | 11.87% |
| Median: 160 Co. | ₹432.20 | 32.47 | 1,987 | 0.08% | 13 | +33.73% | 179 | +21.23% | 14.94% |
Filings
Annual reports15
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Newspaper Publication 16 Nov - We herewith enclose the Newspaper Publication for the Unaudited Financial Results of the Company for the Quarter & Half Year ended September 30, 2026 as …Unaudited Financial Results For The Quarter And Half Year Ended September 30, 2026 11 NovBoard Meeting Outcome for The Board Meeting Held On 11/11/2026 11 Nov - Bafna approved Q2/H1 FY27 results and disclosed GST demands of ₹235.47 lakh and ₹331.09 lakh.Board Meeting Intimation for Meeting Scheduled On November 11, 2026 6 Nov - Board meets November 11, 2026 to approve Q2 and half-year unaudited results; trading window closed till November 13.Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 12 Oct - Certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended September 30, 2026






